Connect with us

Uncategorized

Biotech Bonanza 2024Biotech Outlook As The Fed Turns Dovish

The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield.In 2024, the 10-year yield should favorably support…

Published

on

The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield.
In 2024, the 10-year yield should favorably support biotech stocks.
Promising advancements in weight loss drugs, neuroscience, oncology, and gene editing treatments offer the potential for biotech growth in 2024.
M&A picked up pace in December to its fastest level in 2023. Transaction activity should remain strong in 2024 and well ahead of last year.
Biotechnology is well positioned to outperform the broader indexes in 2024, provided the 10-year yield remains below 4%, with potential gains of 20%-25% and likely higher.

Biotech Pulse

Investing in biotechs in 2023 proved challenging as the burden of a rising 10-year Treasury yield pushed the industry group to new yearly lows. As recently as last October, the industry group was trading at levels seen during March 2020, when the pandemic-related selloff occurred. The biotech industry group started its rebound in November, driven by a decline in the 10-year Treasury yield, which allowed the biotech index to recover its losses and gain a little ground for the year.

Performance of the Nasdaq Biotechnology Index and Prudent Biotech model portfolio.

In the 2023 biotech outlook, we had projected for the Nasdaq Biotech Index to rise in the high teens, acknowledging the pivotal importance of the 10-year yield and stating that:
Under the assumption that the 10-year yield will not make new highs this year, we anticipate the biotech group to deliver returns of 15% and perhaps higher during 2023."

However, rising yields throughout the year tested this assumption.

Biotech's Path In 2024

This is the year the Fed Funds rate will begin its descent. A shift in monetary policy from rate hikes to rate cuts is generally positive for the stock market. However, if the rate cuts are mostly a result of a material drop in economic activity, that will pose a serious challenge for many industry groups. For biotechs, lower earnings growth issues should be mitigated and the group is likely to have a standout year.

10-Year Treasury Yield To Favor Biotechs

The direction of the 10-year yield significantly influences biotech performance. As the yield trends lower, it stimulates valuations, removing a hurdle for stocks, particularly biotechs. Stocks can rise even with gradually rising yields when economic growth overcomes the yield penalty. However, investors are likely to encounter a different environment in 2024.

Biotechs were on a slippery slope in 2023 due to the yield on the benchmark 10-year Treasury note surging from ~3% in March to 5% in October. When the yield began to drop last November, biotech valuations remained mired at their lows. It is this divergence that we pointed out in a November article, Biotech Stocks Ready to Roar, recommending a strong exposure to the industry group.

The robust negative correlation between the yield curve's trajectory and the biotech industry's fortunes is presented below. The highlighted section in the image from the last article shows a yield decline with no corresponding gains for the biotech index at that time.

Correlation between 10-Year Bond Yield and the S&P Biotechnology Index

In 2024, the 10-year yield is likely to be more supportive of biotech valuations, notwithstanding occasional and transitory yield spikes, and it should settle below 4%. Yields don't have to keep falling for biotech stocks to outperform. Even stabilizing at the present lower levels will diminish concerns and allow trial results and pipeline prospects to drive biotech valuations. 

With the Fed expressing its intent to align its restrictive policy to reflect real rates, there appear to be more reasons for yields to trend lower than higher at this time. Nonetheless, forecasting yield is a hazardous task and the risk must be monitored.

Pushing the Frontiers in Medical Science

There is notable progress being achieved as biotech and pharmaceutical companies move forward to deliver some ground-breaking treatments.

Weight Loss Drugs

One such treatment is the glucagon-like peptide 1 (GLP-1), also referred to as gut hormone, weight loss class of drugs.

Novo Nordisk's (NVO) drug, Ozempic, and Eli Lilly's (LLY) drug, Mounjaro, are presently the only approved GLP-1 weight loss treatments targeting the mass market. Last month, Pfizer (PFE) announced that it will abandon developing its twice-daily version of the weight loss pill Danuglipron due to tolerability issues, although it still plans to release Phase 2 data in the second quarter on its daily version of the drug. Merck (MRK) has development efforts in this segment with its experimental drug Efinopegdutide, which is being targeted for patients with a progressive liver disease called nonalcoholic steatohepatitis, or NASH, but has potential as a weight loss drug.

There are quite a few biotechs with approved or development-stage weight loss drugs, including Rhythm Pharmaceuticals (RYTM) which received approval for its drug Imcivree in 2022, Soleno Therapeutics (SLNO), and Altimmune (ALT). Pfizer recently estimated that the market opportunity for weight loss drugs could surge to $90 billion and the company would target 10% of it.

Neurology

There is tangible progress in managing Alzheimer's disease, which afflicts over 7 million Americans. However, the road to an effective treatment is long.

In January 2023, the drug Leqembi from Eisai and Biogen (BIIB) was approved by the FDA in an accelerated approval. It showed a slower decline in cognitive function in cases of mild cognitive impairment due to Alzheimer's disease. In October 2023, Eisai reported further progress with an injectable version of Leqembi which showed more efficacy in an early-stage clinical trial, removing 14% more plaque than the approved intravenous formulation. If approved in a few years, the injectable version will make it much easier to administer the drug and further expand the market.

There was further progress on the Alzheimer's front when Eli Lilly reported in July 2023 that its drug Donanemab, which works on the same amyloid beta reduction hypothesis as Leqembi, significantly slowed cognitive decline in people living with mild cognitive impairment or mild dementia. The drug is expected to receive FDA approval in the first quarter of 2024, which would add to Eli Lilly's recent success in developing blockbuster drugs.

Visual cortex of a person with Alzheimer's disease (Massachusetts General Hospital, The New York Times, edits by PrudentBiotech.com)

Above is an actual image of the visual cortex of a person with Alzheimer’s disease. The giant blue web is depicting brain cells called astrocytes, which typically help form and protect the brain’s connections. Based on advancing research and a recent set of images, including this one, it appears that astrocytes can engulf and attack the brain’s synapses (shown here as fluorescent dots), which contributes to the deterioration of the mind. Researchers with the Brain Atlas, a project that began in 2017, have identified some 3,300 types of brain cells or neurons and have only a dim notion of the function of most of these cells. Identifying the functionally distinct types of neurons, which are the elementary computational elements that collectively create the brain, is critical to an understanding of how the brain works. The path remains long and challenging.

Neuroscience research is a focus for many companies, including Karuna Therapeutics (KRTX), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Intra-Cellular Therapies (ITCI), Axsome Therapeutics (AXSM), Prothena (PRTA), and Cassava Sciences (SAVA).

Oncology

Oncology remains the largest market opportunity and one that receives the most research funding from pharmaceutical and biotech companies. There has been continued progress on CAR-T and allogeneic therapies. 

One area of groundbreaking progress is cancer vaccines. Merck (MRK) and Moderna (MRNA) have been combining their respective expertise in immuno-oncology and mRNA technology in developing cancer vaccines. After promising data in 2022, the companies built further on the progress, and a few weeks ago reported highly favorable data from a Phase 2b trial, with the combination of the vaccine and Keytruda reducing the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62%, compared to Keytruda alone, in stage III/IV melanoma patients with high risk of recurrence following complete resection. The companies have also initiated a Phase 3 trial in non-small cell lung cancer and plan to expand the development program to additional tumor types. 

Cancer vaccines are coming and will expand the options for patients to combat cancer.

Gene Editing

Gene editing treatments are advancing into approved therapies, highlighting the effectiveness of the approach to deliver targeted and transformative treatments, especially for patients with rare diseases that have limited treatment options. Last month, the FDA approved a groundbreaking treatment for sickle cell disease, the first such approval of a treatment using CRISPR gene editing technique. The treatment was co-developed by Crispr Therapeutics (CRSP), using its gene-editing technology, and Vertex Pharmaceuticals (VRTX). Management consulting firm McKinsey estimates that 30 new cell and gene therapies can come to market in 2024, up from 1 in 2023.

The cornucopia of platform-driven approaches from RNA to gene editing to oncology therapies underscores the relentless quest for treatments and the potential for many new drug discoveries during 2024.

M&A and Partnerships

In our November update to Prudent Biotech members, we noted that the realization that interest rates have likely peaked will indicate that biotech valuations have bottomed out and thus, should spur biotech acquisition activity.

Last December was the busiest transaction month for 2023 with six transactions worth more than $40 billion. The largest of these was the acquisition of Karuna Therapeutics for $14 billion by Bristol Myers Squibb (BMY), and two acquisitions by AbbVie (ABBV) of Cerevel Therapeutics (CERE) and Immunogen (IMGN) for a combined $19 billion. Neuroscience and oncology specialties dominated the transactions during December.

We believe the timing seems highly favorable for a strong M&A year and 2024 activity has the potential to be the strongest in recent memory. With significant pressure on pharmaceuticals and large biotechnology companies to grow pipelines, the existing low relative return on in-house R&D of pharmaceutical companies, and a shift in the interest rate trend signaling a bottom for biotech valuations, there is little reason for large biopharmas to wait.

Drug Price Regulation

A prominent risk for the pharmaceutical and biotech industry groups is the conflict around drug price regulation.

As part of the Inflation Reduction Act, the Center for Medicare & Medicaid Services (CMS) acquired the authority to negotiate prices for Medicare in 2024. The process started last year with the identification of 10 drugs to be negotiated in the first round, and the actual price negotiation will begin on February 1 when CMS offers its initial “maximum price” for these drugs. After a window for negotiations with the drug manufacturers, the CMS will make its final price offer on July 15. If the drug manufacturer does not accept then they will have to pay a steep excise tax on US sales of that drug or withdraw from Medicare and Medicaid coverage. The pharma industry is fighting the issue in the courts and decisions are likely to start coming by mid-year.

The drug price negotiation is the first time the industry has faced such a forceful challenge on high drug prices, and it can lead to lower prices, lower revenues, and lower profit margins for the industry. The issue has cast a long shadow on pharmaceuticals but is unlikely to adversely impact M&A valuations for small-to-mid-sized biotechs.

Conclusion

The biotechnology industry appears to be well positioned to outperform the broader indexes in 2024, provided the 10-year yield remains below 4%. It will not be surprising for the 10-year yield to spike in some months. However, the trend for yields during 2024 is very likely to be a downward one and should be reassuring for biotech investors.

A big risk for the stock market is a slower timetable for rate cuts pursued by the Fed, who may decide to walk back the aggressive market expectations. A decision from the next Fed meeting will be announced on January 31. There could be potential headwinds including a slowdown in earnings growth perhaps as early as the upcoming earnings season beginning mid-January. There are also uncertainties related to a Presidential election year, typically favorable for stocks but raises the risk in the months immediately preceding the election, the inability of the House thus far to pass a government funding bill with the next deadline of January 19, and global geopolitical risks. The stock market is heavily overbought presently and is likely to experience a natural pullback shortly.

Biotechs have been consolidating in a range for two years. That period of consolidation cannot be underestimated and can prove to be a springboard as market conditions turn favorable, which appears to be happening.

A confluence of low relative valuations, diminishing yield concerns, an improving risk environment, an accelerating pace of M&A, industry group rotation in case of economic concerns, and a lengthy consolidation period, all position the biotech group for a forceful advance during 2024. We estimate biotech indexes are positioned to deliver returns of 20% to 25%, and likely even higher, in 2024.

With the overarching trends shifting in favor of biotechnology, there are many promising companies that can outperform in 2024. A few of these, which may already be part of the Prudent Biotech, the Prudent Healthcare, and the Prudent Small Cap model portfolios, include Vertex Pharmaceuticals (VRTX), Moderna (MRNA), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Acadia Pharmaceuticals (ACAD), Rhythm Pharmaceuticals (RYTM), Neurocrine Biosciences (NBIX), Apellis Pharmaceuticals (APLS), Intracellular Therapies (ITCI), Immunovant (IMVT), BioNTech (BNTX), Ideaya Biosciences (IDYA), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Cymabay Therapeutics (CBAY), Soleno Therapeutics (SLNO), Madrigal Pharmaceuticals (MDGL), ALX Oncology (ALXO), and Crinetics Pharmaceuticals (CRNX).

A major industry event this month is the J.P. Morgan Healthcare Conference from January 8-11. It is the largest healthcare investment symposium providing industry insights and setting the healthcare investment tone for the year. It is often used as a platform for corporate news releases including trial results and M&A.

This outlook expectation is simply a general framework to guide investors about the potential and will need to be adjusted if market conditions deviate materially from current expectations.

The article was first published on Seeking Alpha.

Read More

Continue Reading

Uncategorized

Default: San Francisco Four Seasons Hotel Investors $3 Million Late On Loan As Foreclosure Looms

Default: San Francisco Four Seasons Hotel Investors $3 Million Late On Loan As Foreclosure Looms

Westbrook Partners, which acquired the San…

Published

on

Default: San Francisco Four Seasons Hotel Investors $3 Million Late On Loan As Foreclosure Looms

Westbrook Partners, which acquired the San Francisco Four Seasons luxury hotel building, has been served a notice of default, as the developer has failed to make its monthly loan payment since December, and is currently behind by more than $3 million, the San Francisco Business Times reports.

Westbrook, which acquired the property at 345 California Center in 2019, has 90 days to bring their account current with its lender or face foreclosure.

Related

As SF Gate notes, downtown San Francisco hotel investors have had a terrible few years - with interest rates higher than their pre-pandemic levels, and local tourism continuing to suffer thanks to the city's legendary mismanagement that has resulted in overlapping drug, crime, and homelessness crises (which SF Gate characterizes as "a negative media narrative).

Last summer, the owner of San Francisco’s Hilton Union Square and Parc 55 hotels abandoned its loan in the first major default. Industry insiders speculate that loan defaults like this may become more common given the difficult period for investors.

At a visitor impact summit in August, a senior director of hospitality analytics for the CoStar Group reported that there are 22 active commercial mortgage-backed securities loans for hotels in San Francisco maturing in the next two years. Of these hotel loans, 17 are on CoStar’s “watchlist,” as they are at a higher risk of default, the analyst said. -SF Gate

The 155-room Four Seasons San Francisco at Embarcadero currenly occupies the top 11 floors of the iconic skyscrper. After slow renovations, the hotel officially reopened in the summer of 2021.

"Regarding the landscape of the hotel community in San Francisco, the short term is a challenging situation due to high interest rates, fewer guests compared to pre-pandemic and the relatively high costs attached with doing business here," Alex Bastian, President and CEO of the Hotel Council of San Francisco, told SFGATE.

Heightened Risks

In January, the owner of the Hilton Financial District at 750 Kearny St. - Portsmouth Square's affiliate Justice Operating Company - defaulted on the property, which had a $97 million loan on the 544-room hotel taken out in 2013. The company says it proposed a loan modification agreement which was under review by the servicer, LNR Partners.

Meanwhile last year Park Hotels & Resorts gave up ownership of two properties, Parc 55 and Hilton Union Square - which were transferred to a receiver that assumed management.

In the third quarter of 2023, the most recent data available, the Hilton Financial District reported $11.1 million in revenue, down from $12.3 million from the third quarter of 2022. The hotel had a net operating loss of $1.56 million in the most recent third quarter.

Occupancy fell to 88% with an average daily rate of $218 in the third quarter compared with 94% and $230 in the same period of 2022. -SF Chronicle

According to the Chronicle, San Francisco's 2024 convention calendar is lighter than it was last year - in part due to key events leaving the city for cheaper, less crime-ridden places like Las Vegas

Tyler Durden Sun, 03/17/2024 - 18:05

Read More

Continue Reading

Uncategorized

Correcting the Washington Post’s 11 Charts That Are Supposed to Tell Us How the Economy Changed Since Covid

The Washington Post made some serious errors or omissions in its 11 charts that are supposed to tell us how Covid changed the economy. Wages Starting with…

Published

on

The Washington Post made some serious errors or omissions in its 11 charts that are supposed to tell us how Covid changed the economy.

Wages

Starting with its second chart, the article gives us an index of average weekly wages since 2019. The index shows a big jump in 2020, which then falls off in 2021 and 2022, before rising again in 2023.

It tells readers:

“Many Americans got large pay increases after the pandemic, when employers were having to one-up each other to find and keep workers. For a while, those wage gains were wiped out by decade-high inflation: Workers were getting larger paychecks, but it wasn’t enough to keep up with rising prices.”

That actually is not what its chart shows. The big rise in average weekly wages at the start of the pandemic was not the result of workers getting pay increases, it was the result of low-paid workers in sectors like hotels and restaurants losing their jobs.

The number of people employed in the low-paying leisure and hospitality sector fell by more than 8 million at the start of the pandemic. Even at the start of 2021 it was still down by over 4 million.

Laying off low-paid workers raises average wages in the same way that getting the short people to leave raises the average height of the people in the room. The Washington Post might try to tell us that the remaining people grew taller, but that is not what happened.

The other problem with this chart is that it is giving us weekly wages. The length of the average workweek jumped at the start of the pandemic as employers decided to work the workers they had longer hours rather than hire more workers. In January of 2021 the average workweek was 34.9 hours, compared to 34.4 hours in 2019 and 34.3 hours in February.

This increase in hours, by itself, would raise weekly pay by 2.0 percent. As hours returned to normal in 2022, this measure would misleadingly imply that wages were falling.

It is also worth noting that the fastest wage gains since the pandemic have been at the bottom end of the wage distribution and the Black/white wage gap has fallen to its lowest level on record.

Saving Rates

The third chart shows the saving rate since 2019. It shows a big spike at the start of the pandemic, as people stopped spending on things like restaurants and travel and they got pandemic checks from the government. It then falls sharply in 2022 and is lower in the most recent quarters than in 2019.

The piece tells readers:

“But as the world reopened — and people resumed spending on dining out, travel, concerts and other things that were previously off-limits — savings rates have leveled off. Americans are also increasingly dip into rainy-day funds to pay more for necessities, including groceries, housing, education and health care. In fact, Americans are now generally saving less of their incomes than they were before the pandemic.

This is an incomplete picture due to a somewhat technical issue. As I explained in a blogpost a few months ago, there is an unusually large gap between GDP as measured on the output side and GDP measured on the income side. In principle, these two numbers should be the same, but they never come out exactly equal.

In recent quarters, the gap has been 2.5 percent of GDP. This is extraordinarily large, but it also is unusual in that the output side is higher than the income side, the opposite of the standard pattern over the last quarter century.

It is standard for economists to assume that the true number for GDP is somewhere between the two measures. If we make that assumption about the data for 2023, it would imply that income is somewhat higher than the data now show and consumption somewhat lower.

In that story, as I showed in the blogpost, the saving rate for 2023 would be 6.8 percent of disposable income, roughly the same as the average for the three years before the pandemic. This would mean that people are not dipping into their rainy-day funds as the Post tells us. They are spending pretty much as they did before the pandemic.

 

Credit Card Debt

The next graph shows that credit card debt is rising again, after sinking in the pandemic. The piece tells readers:

“But now, debt loads are swinging higher again as families try to keep up with rising prices. Total household debt reached a record $17.5 trillion at the end of 2023, according to the Federal Reserve Bank of New York. And, in a worrisome sign for the economy, delinquency rates on mortgages, car loans and credit cards are all rising, too.”

There are several points worth noting here. Credit card debt is rising, but measured relative to income it is still below where it was before the pandemic. It was 6.7 percent of disposable income at the end of 2019, compared to 6.5 percent at the end of last year.

The second point is that a major reason for the recent surge in credit card debt is that people are no longer refinancing mortgages. There was a massive surge in mortgage refinancing with the low interest rates in 2020-2021.

Many of the people who refinanced took additional money out, taking advantage of the increased equity in their home. This channel of credit was cut off when mortgage rates jumped in 2022 and virtually ended mortgage refinancing. This means that to a large extent the surge in credit card borrowing is simply a shift from mortgage debt to credit card debt.

The point about total household debt hitting a record can be said in most months. Except in the period immediately following the collapse of the housing bubble, total debt is almost always rising.

And the rise in delinquencies simply reflects the fact that they had been at very low levels in 2021 and 2022. For the most part, delinquency rates are just getting back to their pre-pandemic levels, which were historically low.  

 

Grocery Prices and Gas Prices

The next two charts show the patterns in grocery prices and gas prices since the pandemic. It would have been worth mentioning that every major economy in the world saw similar run-ups in prices in these two areas. In other words, there was nothing specific to U.S. policy that led to a surge in inflation here.

 

The Missing Charts

There are several areas where it would have been interesting to see charts which the Post did not include. It would have been useful to have a chart on job quitters, the number of people who voluntarily quit their jobs during the pandemic. In the tight labor markets of 2021 and 2022 the number of workers who left jobs they didn’t like soared to record levels, as shown below.

 

The vast majority of these workers took other jobs that they liked better. This likely explains another item that could appear as a graph, the record level of job satisfaction.

In a similar vein there has been an explosion in the number of people who work from home at least part-time. This has increased by more than 17 million during the pandemic. These workers are saving themselves thousands of dollars a year on commuting costs and related expenses, as well as hundreds of hours spent commuting.

Finally, there has been an explosion in the use of telemedicine since the pandemic. At the peak, nearly one in four visits with a health care professional was a remote consultation. This saved many people with serious health issues the time and inconvenience associated with a trip to a hospital or doctor’s office. The increased use of telemedicine is likely to be a lasting gain from the pandemic.

 

The World Has Changed

The pandemic will likely have a lasting impact on the economy and society. The Washington Post’s charts captured part of this story, but in some cases misrepr

The post Correcting the Washington Post’s 11 Charts That Are Supposed to Tell Us How the Economy Changed Since Covid appeared first on Center for Economic and Policy Research.

Read More

Continue Reading

Uncategorized

Women’s basketball is gaining ground, but is March Madness ready to rival the men’s game?

The hype around Caitlin Clark, NCAA Women’s Basketball is unprecedented — but can its March Madness finally rival the Men’s?

Published

on

In March 2021, the world was struggling to find its legs amid the ongoing Covid-19 pandemic. Sports leagues were trying their best to keep going.

It started with the NBA creating a bubble in Orlando in late 2020, playing a full postseason in the confines of Disney World in arenas that were converted into gyms devoid of fans. Other leagues eventually allowed for limited capacity seating in stadiums, including the NCAA for its Men’s and Women’s Basketball tournaments.

The two tournaments were confined to two cities that year — instead of games normally played in different regions around the country: Indianapolis for the men and San Antonio for the women.

But a glaring difference between the men’s and women’s facilities was exposed by Oregon’s Sedona Prince on social media. The workout and practice area for the men was significantly larger than the women, whose weight room was just a single stack of dumbbells.

The video drew significant attention to the equity gaps between the Men’s and Women’s divisions, leading to a 114-page report by a civil rights law firm that detailed the inequities between the two and suggested ways to improve the NCAA’s efforts for the Women’s side. One of these suggestions was simply to give the Women’s Tournament the same March Madness moniker as the men, which it finally got in 2022.

But underneath the surface of these institutional changes, women’s basketball’s single-biggest success driver was already emerging out of the shadows.

During the same COVID-marred season, a rookie from Iowa led the league in scoring with 26.6 points per game.

Her name: Caitlin Clark.

Caitlin Clark has scored the most points and made the most threes in college basketball.

Matthew Holst/Getty Images

As it stands today, Clark is the leading scorer in the history of college basketball — Men’s or Women’s. Her jaw-dropping shooting ability has fueled record viewership and ticket sales for Women’s collegiate games, carrying momentum to the March Madness tournament that has NBA legends like Kevin Garnett and Paul Pierce more excited for the Women’s March Madness than the Men’s this year.

Related: Ticket prices for Caitlin Clark's final college home game are insanely high

But as the NCAA tries to bridge the opportunities given to the two sides, can the hype around Clark be enough for the Women’s March Madness to bring in the same fandom as the Men for the 2024 tournaments?

TheStreet spoke with Jon Lewis of Sports Media Watch, who has been following sports viewership trends for the last two decades; Melissa Isaacson, a veteran sports journalist and longtime advocate of women’s basketball; and Pete Giorgio, Deloitte’s leader for Global and US Sports to dissect the rise Caitlin Clark and women’s collegiate hoops ahead of March Madness.

“Nobody is moving the needle like Caitlin Clark,” Lewis told TheStreet. “Nobody else in sports, period, right now, is fueling record numbers on all these different networks, driving viewership beyond what the norm has been for 20 years."

The Caitlin Clark Effect is real — but there are other reasons for the success of women's basketball

The game in which Clark broke the all-time college scoring record against Ohio State on Sunday, Mar. 3 was seen by an average of 3.4 million viewers on Fox, marking the first time a women’s game broke the two million viewership barrier since 2010. Viewership for that game came in just behind the men’s game between Michigan State vs Arizona game on Thanksgiving, which Lewis said was driven by NFL viewership on the same day.

A week later, Iowa’s Big Ten Championship win over Nebraska breached the three million viewers mark as well, and the team has also seen viewership numbers crack over 1.5 million viewers multiple times throughout the regular season.

The success on television has also translated to higher ticket prices, as tickets to watch Clark at home and on the road have breached hundreds of dollars and drawn long lines outside stadiums. Isaacson, who is a professor at Northwestern, said she went to the game between the Hawkeyes and Northwestern Wildcats — which was the first sellout in school history for the team — and witnessed the effect of Clark in person.

“Standing in line interviewing people at the Northwestern game, seeing men who've never been to a women's game with their little girls watching and so excited, and seeing Caitlin and her engaging with little girls, it’s just been really fun,” Isaacson said.

But while Clark is certainly the biggest success driver, her game isn’t the only thing pulling up the women’s side. The three-point revolution, which started in the NBA with the introduction of deeper analytics as well as the rise of stars like Steph Curry, has been a positive for the Women’s game.

“They backed up to the three-point line and it’s opening up the game,” Isaacson said.

One of the major criticisms from a lot of women’s hoops detractors has been how the game does not compare in terms of quality to the men. However, shooting has become a great equalizer, displayed recently during the 2024 NBA All-Star Weekend last month when the WNBA’s Sabrina Ionescu nearly defeated Curry — who is widely considered the greatest shooter ever — in a three-point contest.

Clark has become the embodiment of the three-point revolution for the women. Her shooting displays have demanded the respect of anyone who has doubted women’s basketball in the past because being a man simply doesn’t grant someone the ability to shoot long-distance bombs the way she can.

Basketball pundit Bill Simmons admitted on a Feb. 28 episode of “The Bill Simmons Podcast” that he used to not want to watch women’s basketball because he didn’t enjoy watching the product, but finds himself following the women’s game this year more than the men’s side in large part due to Clark.

“I think she has the chance to be the most fun basketball player, male or female, when she gets to the pros,” Simmons said. “If she’s going to make the same 30-footers, routinely. It’s basically all the same Curry stuff just with a female … I would like watching her play in any format.”

But while Clark is driving up the numbers at the top, she’s not the only one carrying the greatness of the product. Lewis, Isaacson, Giorgio — and even Simmons, on his podcast — agreed that there are several other names and collegiate programs pulling in fans.

“It’s not just Iowa, it’s not just Caitlin Clark, it’s all of these teams,” Giorgio said. “Part of it is Angel Reese … coaches like Dawn Staley in South Carolina … You’ve got great stories left and right.”

LSU's Angel Reese (right) and her head coach Kim Mulkey are two of the biggest names in Women's college hoops. 

Eakin Howard/Getty Images

The viewership showed that as well because the SEC Championship game between the LSU Tigers and University of South Carolina Gamecocks on Sunday, Mar. 10 averaged two million viewers.

Bridging the gap between the Men’s and Women’s March Madness viewership

The first reason women are catching up to the men is really star power. While the Women’s division has names like Clark and Reese, there just aren’t any names on the Men’s side this year that carry the same weight.

Garnett said on his show that he can’t name any men’s college basketball players, while on the women’s side, he could easily throw out the likes of Clark, Reese, UConn’s Paige Bueckers, and USC’s JuJu Watkins. Lewis felt the same.

“The stars in the men's game, with one and done, I genuinely couldn't give you a single name of a single men’s player,” Lewis said.

A major reason for this is that the Women’s side has the continuity that the Men’s side does not. The rules of the NBA allow for players to play just one year in college — or even play a year professionally elsewhere — before entering the draft, while the WNBA requires players to be 22-years-old during the year of the draft to be eligible.

“You know the stars in the women's game because they stay longer,” Lewis said. “[In the men’s game], the programs are the stars … In the women's game, it's a lot more like the NBA where the players are the stars.”

Parity is also a massive factor on both sides. The women’s game used to be dominated by a few schools like UConn and Notre Dame. Nowadays, between LSU, Iowa, University of South Carolina, Stanford, and UConn, there are a handful of schools that have a shot to win the entire tournament. While this is more exciting for fans, the talent in the women's game isn’t deep enough, so too many upsets are unlikely. Many of the biggest draws are still expected to make deep runs.

But on the men’s side, there is a bigger shot that the smaller programs make it to the end — which is what was seen last year. UConn eventually won the whole thing, but schools without as big of a national fanbase in San Diego State, Florida Atlantic University, and the University Miami rounded out the Final Four.

“People want to see one Cinderella,” Lewis said. “They don't want to see two and three, they want one team that isn't supposed to be there.”

Is Women's March Madness ready to overtake the Men?

Social media might feel like it’s giving more traction to the Women’s game, but experts don’t necessarily expect that to show up in the viewership numbers just yet.

“There’s certainly a lot more buzz than there used to be,” Giorgio said. “It’s been growing every year for not just the past few years but for 10 years, but it’s hard to compare it versus Men’s.”

But the gap continues to get smaller and smaller between the two sides, and this year's tournament could bridge that gap even further.

One indicator is ticket prices. For the NCAA Tournament Final Four in April, “get-in” ticket prices are currently more expensive for the Women’s game than the Men’s game, according to TickPick. The ticketing site also projects that the Women’s Final Four and Championship game ticket prices will smash any previous records for the Women’s side should Clark and the Hawkeyes make a run to the end.

NCAA "get-in" price comparison.

Getty Images/TheStreet

The caveat is that the Women’s Final Four is played in a stadium that has less than a third of the seating capacity of the Men’s Final Four. That’s why the average ticket prices are still more expensive for the men, although the gap is a lot smaller this year than in previous years.

The gap between the average ticket prices of the Final Four tournaments is getting smaller.

But that caveat pretty much sums up where the women’s game currently stands versus the men’s: There is still a significant gap between the distribution and availability of the former.

While Iowa’s regular season games have garnered millions of viewers, the majority of the most-viewed games are still Men’s contests.

To illustrate the gap between the men’s and women’s game — last year’s Women’s Championship game that saw the LSU Tigers defeat the Hawkeyes was a record-breaking one for the women, drawing an average of 9.9 million viewers, more than double the viewership from the previous year.

One of the main reasons for that increase, as Lewis pointed out, is that last year’s Championship game was on ABC, which was the first time since 1995 that the Women’s Championship game was on broadcast television. The 1995 contest between UConn and Tennessee drew 7.4 million viewers.

The Men’s Championship actually had a record low in viewership last year garnering only 14.7 million viewers, driven in-part due to a lack of hype surrounding the schools that made it to the Final Four and Championship game. Viewership for the Men’s title game has been trending down in recent years — partly due to the effect the pandemic had on collective sports viewership — but the Men’s side had been easily breaching 20 million viewers for the game as recently as 2017.

The 2023 Women's National Championship was the most-viewed game ever, while the Men's Championship was the division's least watched. 

Iowa's Big Ten Championship win on Sunday actually only averaged 6,000 fewer viewers than the iconic rivalry game between Duke and University of North Carolina Men’s Basketball the day prior. However, there is also the case that the Iowa game was played on broadcast TV (CBS) versus the Duke-UNC game airing on cable channel (ESPN).

So historical precedence makes it unlikely that we’ll see the women’s game match the men’s in terms of viewership as early as this year barring another massive viewership jump for the women and a lack of recovery for the Men’s side.

But ultimately, this shouldn’t be looked at as a down point for Women’s Basketball, according to Lewis. The Men’s side has built its viewership base for years, and the Women’s side is still growing. Even keeping pace with the Men’s viewership is already a great sign.

“The fact that these games have Caitlin Clark are even in the conversation with men's games, in terms of viewership is a huge deal,” Lewis said.

Related: Angel Reese makes bold statement for avoiding late game scuffle in championship game

Read More

Continue Reading

Trending